Physician profile
David E Carr
NPI 1720008717
$1,644.37
in general payments reported to CMS, 2019-2025
12 companies · $19.75 in 2025
The $19.75 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $220 · 2021: $323 · 2022: $164 · 2023: $115 · 2024: $88.88 · 2025: $19.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $132 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $131.93 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $430.85 | 2019-2025 | Invega Sustenna |
| Abbvie INC. | $252.72 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $186.41 | 2019-2021 | |
| Alkermes, INC. | $183.99 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $150.22 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $130.65 | 2019-2024 | Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $91.49 | 2023 | |
| Allergan, INC. | $87.23 | 2019-2020 | |
| Cochlear Americas | $84.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.17 | 2024 | |
| Avanir Pharmaceuticals, INC. | $11.58 | 2019 | |
| Creo Medical INC. | $6.04 | 2023 | Speedboat |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.